Search

everythinglearnresearchcommunity

for

Search:↓

User 74775446 shares successful hair regrowth results using dermaroller/pen and minoxidil. Others discuss their experiences and concerns about finasteride side effects.

The conversation discusses the application of RU58841 for hair loss, with the user applying 1.75 mg at 5% concentration for half an hour daily. The user mentions managing seborrheic dermatitis while using this treatment.

RU58841's legitimacy and sourcing concerns. Users suggest caution and recommend trusted sources over platforms like Amazon.

Dermapen is considered more effective and easier to use than dermaroller and dermastamp for hair loss treatment, though results vary. Dermastamp is affordable but less convenient, while dermapen is more precise but can be bloody.

Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.

The conversation discusses a user's two-month hair regrowth progress using Minoxidil and a 0.5mm dermaroller. Some suggest adding a 5-alpha-reductase inhibitor like finasteride or dutasteride to maintain the results.

A fake hair loss product called "PP405" is being humorously discussed, with users joking about its effectiveness and availability on resale websites. The consensus is that it's a scam, with some users sarcastically claiming miraculous results.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

RU58841 powder may degrade over time, even when stored in a freezer. Users discuss its potential effectiveness after three years of storage.

User shares 2-month progress with fin, min, dermarolling. Others discuss consistency, regrowth, shedding, and potential side effects.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

A 28-year-old is experiencing hair loss despite using treatments like oral minoxidil, finasteride, and high-dose dutasteride (2.5 mg). They suspect lichen planus might be contributing to the issue and plan to continue treatment while monitoring progress.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

The conversation is about finding a source for Alfatradiol 0.1% as most available products are 0.025%. A suggestion was made to use four times the dosage of the 0.025% product.

A user shared their initial experiences with The Ordinary hair density serum, which contains Redensyl (taxifolin). They observed increased hair volume but also developed pimples, likely due to the serum stimulating sebaceous glands.

The conversation discusses hair regrowth using finasteride, minoxidil, and a dermaroller. Users also talk about the benefits of using a stamp over a derma roller for scalp treatment.

The user plans to use a 1.5 mm dermapen for microneedling every 10 days and is considering applying aloe vera afterward. They also inquire about the timing for washing their hair before and after the treatment.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.

OP bought Koshine x826 and plans to update on its effectiveness, currently using fluridil. OP couldn't tolerate RU or DUT, while another user mixes Dutasteride with Koshine x826 weekly without side effects.

A user's hair growth progress over 5 months using Fin 2.5mg gel and Redensyl serum, with the user noticing baby hairs and an improvement in thickness. Another user asked what redensyl serum was and the response was appreciation for noticing the hair loss early on.

Treating hair loss with dermarolling and other treatments such as Minoxidil, Finasteride, and RU58841.

The conversation is about a user complaining about the strong smell of a stemoxydine serum used for hair loss. Other users suggest that the product might be counterfeit due to its unpleasant odor.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

Pyrilutamide 0.9% (kx-826) is available for shipping to Europe from Amazon US and Koshinemall. Shipping costs and availability vary between the two shops.

The user is considering adding Stemoxydine to their hair loss regimen, as they already use topical finasteride with rosemary and cannot use Minoxidil. They are seeking feedback on Stemoxydine and Alphatradiol, and another user mentions 2-deoxy-d-ribose as a potential option.

The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.

A user shared their 6-month progress using a dermaroller and a homemade shampoo made of rosemary water, aloe vera, and vitamin E for hair loss. They provided a link to photos showing their results.

The user experienced significant hair regrowth using dermarolling, peppermint essential oil, rosemary carrier oil, finasteride, dutasteride, biotin, vitamin E, spirulina, fish oil, and a protein-rich diet. The oral versions of finasteride and dutasteride were noted as more effective.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.